{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:39:29Z","timestamp":1789389569770,"version":"build-2803163510"},"reference-count":41,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,2,1]]},"DOI":"10.1210\/jc.2002-021122","type":"journal-article","created":{"date-parts":[[2003,2,6]],"date-time":"2003-02-06T20:45:23Z","timestamp":1044564323000},"page":"569-575","source":"Crossref","is-referenced-by-count":155,"title":["Short-Term, High-Dose Parathyroid Hormone-Related Protein as a Skeletal Anabolic Agent for the Treatment of Postmenopausal Osteoporosis"],"prefix":"10.1210","volume":"88","author":[{"given":"Mara J.","family":"Horwitz","sequence":"first","affiliation":[{"name":"Division of Endocrinology (M.J.H., M.B.T., A.G.-O., A.F.S.), The University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Tedesco","sequence":"additional","affiliation":[{"name":"Division of Endocrinology (M.J.H., M.B.T., A.G.-O., A.F.S.), The University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caren","family":"Gundberg","sequence":"additional","affiliation":[{"name":"Department of Orthopedics (C.G.), Yale University School of Medicine, New Haven, Connecticut 06520"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Garcia-Ocana","sequence":"additional","affiliation":[{"name":"Division of Endocrinology (M.J.H., M.B.T., A.G.-O., A.F.S.), The University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Division of Endocrinology (M.J.H., M.B.T., A.G.-O., A.F.S.), The University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2019041117340705400_R1","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jama.1996.03540170033029","article-title":"The effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen\/progestin interventions (PEPI) trial.","volume":"276","year":"1996","journal-title":"JAMA"},{"key":"2019041117340705400_R2","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis.","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"2019041117340705400_R3","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effect of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women.","volume":"337","author":"Delmas","year":"1997","journal-title":"N Engl J Med"},{"issue":"suppl 3","key":"2019041117340705400_R4","first-page":"13","article-title":"Salmon calcitonin nasal spray prevents vertebral fractures in established osteoporosis","volume":"8","author":"Chestnut","year":"1998","journal-title":"Further interim results of the PROOF study. Osteoporos Int"},{"key":"2019041117340705400_R5","first-page":"1895","article-title":"Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, controlled clinical trial.","volume":"85","author":"Fogelman","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117340705400_R6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women.","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"2019041117340705400_R7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zolendronic acid in postmenopausal women with low bone mineral density.","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"key":"2019041117340705400_R8","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1210\/jcem.86.3.7366","article-title":"Anabolic therapy for osteoporosis.","volume":"86","author":"Rosen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117340705400_R9","first-page":"690","article-title":"Anabolic actions of parathyroid hormone on bone.","volume":"14","author":"Dempster","year":"1993","journal-title":"Endocr Rev"},{"key":"2019041117340705400_R10","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199412153312404","article-title":"Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency.","volume":"331","author":"Finkelstein","year":"1994","journal-title":"N Engl J Med"},{"key":"2019041117340705400_R11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised clinical trial of the effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women with osteoporosis.","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"2019041117340705400_R12","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1359\/jbmr.2001.16.5.925","article-title":"Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.","volume":"16","author":"Cosman","year":"2001","journal-title":"J Bone Miner Metab"},{"key":"2019041117340705400_R13","first-page":"620","article-title":"A randomized controlled clinical trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.","volume":"82","author":"Hodsman","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117340705400_R14","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI3914","article-title":"Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis.","volume":"102","author":"Lane","year":"1998","journal-title":"J Clin Invest"},{"key":"2019041117340705400_R15","first-page":"59","article-title":"Treatment of postmenopausal osteoporosis with human parathyroid hormone 1\u201334 and estrogen","volume-title":"Program of the 81st Annual Meeting of The Endocrine Society","author":"Roe","year":"1999"},{"key":"2019041117340705400_R16","first-page":"3069","article-title":"Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.","volume":"85","author":"Kurland","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117340705400_R17","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis.","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"2019041117340705400_R18","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.","volume":"16","author":"Dempster","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2019041117340705400_R19","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117340705400_R20","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.1998.13.6.1051","article-title":"Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.","volume":"13","author":"Cosman","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2019041117340705400_R21","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJM198012113032401","article-title":"Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and non-humoral groups.","volume":"303","author":"Stewart","year":"1980","journal-title":"N Engl J Med"},{"key":"2019041117340705400_R22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1210\/jcem-55-2-219","article-title":"Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity.","volume":"55","author":"Stewart","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117340705400_R23","first-page":"607","article-title":"Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia.","volume":"81","author":"Nakayama","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117340705400_R24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1056\/NEJM200001203420306","article-title":"The physiology of parathyroid hormone-related protein.","volume":"342","author":"Strewler","year":"2000","journal-title":"N Engl J Med"},{"key":"2019041117340705400_R25","doi-asserted-by":"crossref","first-page":"6097","DOI":"10.1016\/S0021-9258(18)83318-X","article-title":"Characterization of canine renal receptors for the parathyroid hormone-like protein associated with humoral hypercalcemia of malignancy.","volume":"264","author":"Orloff","year":"1989","journal-title":"J Biol Chem"},{"key":"2019041117340705400_R26","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.1016\/S0021-9258(18)68339-5","article-title":"The parathyroid hormone-like peptide associated with humoral hypercalcemia of malignancy and parathyroid hormone bind to the same receptor on the plasma membrane of ROS 17\/2.8 cells.","volume":"263","author":"Juppner","year":"1988","journal-title":"J Biol Chem"},{"key":"2019041117340705400_R27","first-page":"377","article-title":"Receptors for parathyroid hormone and parathyroid hormone-related protein","author":"Segre","year":"1996","journal-title":"In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of bone biology. San Diego: Academic Press;"},{"key":"2019041117340705400_R28","first-page":"199","article-title":"Parathyroid hormone-related protein(1\u201336) is equipotent with parathyroid hormone(1\u201334) in humans.","volume":"81","author":"Everhart-Caye","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117340705400_R29","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1359\/jbmr.2000.15.8.1517","article-title":"Six month daily administration of PTH and PTHrP peptides to adult ovariectomized rats markedly enhances bone mass and biomechanics: a comparison of human PTH(1\u201334), PTHrP(1\u201336) and SDZ-PTH-893.","volume":"15","author":"Stewart","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2019041117340705400_R30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1101\/gad.8.3.277","article-title":"Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene.","volume":"8","author":"Karaplis","year":"1994","journal-title":"Genes Dev"},{"key":"2019041117340705400_R31","first-page":"93","article-title":"Parathyroid hormone-related protein is equipotent to parathyroid hormone in both hypercalcemic and anticalciuric actions: implications for humoral hypercalcemia of malignancy","volume-title":"Program of the 84th Annual Meeting of The Endocrine Society","author":"Horwitz","year":"2002"},{"key":"2019041117340705400_R32","first-page":"900","article-title":"Parathyroid hormone-related protein (1\u201336) is biologically active when administered subcutaneously to humans.","volume":"82","author":"Henry","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117340705400_R33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2265.1980.tb01023.x","article-title":"Studies of circulating parathyroid hormone in man using a homologous amino-terminal specific immunoradiometric assay.","volume":"13","author":"Papapoulos","year":"1990","journal-title":"Clin Endocrinol"},{"key":"2019041117340705400_R34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1042\/cs0680171","article-title":"Pharmacokinetics of synthetic human parathyroid hormone 1\u201334 in man measured by cytochemical bioassay and radioimmunoassay.","volume":"68","author":"Kent","year":"1985","journal-title":"Clin Sci"},{"key":"2019041117340705400_R35","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1172\/JCI113358","article-title":"A synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats.","volume":"81","author":"Stewart","year":"1988","journal-title":"J Clin Invest"},{"key":"2019041117340705400_R36","first-page":"2786","article-title":"Dissociation of bone formation from resorption during two-week treatment with hPTHrP(1\u201336) in humans: potential as an anabolic therapy for osteoporosis.","volume":"83","author":"Plotkin","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117340705400_R37","first-page":"3258","article-title":"Vitamin K status and bone health: an analysis of methods for the determination of \u201cundercarboxylated\u201d osteocalcin.","volume":"83","author":"Gundberg","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117340705400_R38","first-page":"1525","article-title":"Parathyroid hormone-related protein (1\u201336) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy.","volume":"86","author":"Syed","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117340705400_R39","first-page":"1535","article-title":"Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1\u201334): kinetics and biochemical response in estrogenized osteoporotic patients.","volume":"77","author":"Lindsay","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041117340705400_R40","first-page":"1305","article-title":"Parathyroid hormone","author":"Hodsman","year":"2002","journal-title":"In: Bilezikian JP, Raisz LR, Rodau GA, eds. Principles of bone biology, ed 2. San Diego: Academic Press;"},{"key":"2019041117340705400_R41","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1210\/endo.138.11.5505","article-title":"Effects of programmed administration of human parathyroid hormone fragment (1\u201334) on bone histomorphometry and serum chemistry in rats.","volume":"138","author":"Dobnig","year":"1997","journal-title":"Endocrinology"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/88\/2\/569\/9148544\/jcem0569.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T17:20:47Z","timestamp":1622740847000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/88\/2\/569\/2845082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,1]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2002-021122","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2,1]]}}}